INTERNATIONAL HEART JOURNAL, vol.49, no.3, pp.303-311, 2008 (Journal Indexed in SCI)
Article / Article
Title of Journal :
INTERNATIONAL HEART JOURNAL
asymmetric dimethylarginine, fluvastatin, metabolic syndrome, ENDOTHELIAL DYSFUNCTION, PLASMA-CONCENTRATIONS, INSULIN-RESISTANCE, STATIN TREATMENT, RISK-FACTOR, ADMA, ATHEROSCLEROSIS, BIOAVAILABILITY, DYSLIPIDEMIA, ROSUVASTATIN
Elevated concentrations of asymmetric dimethylarginine (ADMA), all endogeneous inhibitor of nitric oxide synthase, are associated with endothelial dysfunction. Metabolic syndrome (MetS) is also a condition associated with impaired endothelial function. To test the hypothesis that lipid lowering treatment with a statin lowers ADMA levels, we investigated file effect of fluvastatin treatment on serum ADMA levels in patients with MetS.